Phase 3 Study of Adjuvant V940 and Pembrolizumab in Resected Melanoma

Clinical Trial Grant

Duke Scholars

Principal Investigator April Kelly Scott Salama Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

November 21, 2023

End Date

November 29, 2028

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

November 21, 2023

End Date

November 29, 2028